Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells
Yong Liu(University of Arkansas for Medical Sciences), Paul L. Hermonat(University of Arkansas for Medical Sciences), Fabio Grizzi(Humanitas University), Everardo Cobos(Texas Tech University), Hong You(Harbin Institute of Technology), V. Suzanne Klimberg(University of Arkansas for Medical Sciences), Changxuan You(Nanfang Hospital), Rongcheng Luo(Hebei Medical University), Helen Kay(University of Arkansas for Medical Sciences), Maurizio Chiriva‐Internati(Texas Tech University), Jawahar L. Mehta(Central Arkansas Veterans Healthcare System), C. Krishna Prasad(University of Arkansas for Medical Sciences)
Cited by 19
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467